Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly Hgi9h Rates of Baseline Peripheral Neuropathy

A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly Hgi9h Rates of Baseline Peripheral Neuropathy. American Society for Hematology 47th Annual Meeting. 2005.


© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.